Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company's MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit CAMBRIDGE, Mass. and NEW YORK, April 03, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows:
马萨诸塞州剑桥和纽约，2024 年 4 月 3 日（GLOBE NEWSWIRE）— 黑钻疗法有限公司 纳斯达克股票代码：BDTX）是一家临床阶段的肿瘤学公司，正在开发针对癌症患者致癌突变家族的MasterKey疗法，该公司今天宣布参加即将举行的投资者会议。总裁兼首席执行官Mark Velleca，医学博士，博士的演讲详情如下：
- 23rd Annual Needham Virtual Healthcare Conference presentation at 8:00am ET on Wednesday, April 10, 2024
- Stifel Virtual Targeted Oncology Forum fireside chat at 10:00am ET on Tuesday, April 16, 2024
- Piper Sandler Spring Biopharma Symposium on Wednesday, April 17, 2024, in Boston, Mass.
- 第 23 届年度 Needham 虚拟医疗会议将于美国东部时间 2024 年 4 月 10 日星期三上午 8:00 发表演讲
- Stifel 虚拟靶向肿瘤学论坛将于美国东部时间 2024 年 4 月 16 日星期二上午 10:00 进行炉边谈话
- 派珀·桑德勒春季生物制药研讨会将于2024年4月17日星期三在马萨诸塞州波士顿举行。
Webcasts will be available at the start of the presentations on the investor relations section of the Company's website, www.blackdiamondtherapeutics.com. Replays of the presentations will also be available and archived on the site for 90 days.
网络直播将在公司网站的投资者关系部分的演讲开始时播出， www.blackdiamondther。演示文稿的重播也将在网站上提供并存档90天。
About Black Diamond Therapeutics
关于黑钻疗法
Black Diamond Therapeutics is a clinical-stage oncology company focused on the development of MasterKey therapies that address families of oncogenic mutations in clinically validated targets. The Company's MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat CNS disease. The Company is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR mutant NSCLC and GBM, and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. For more information, please visit www.blackdiamondtherapeutics.com
Black Diamond Therapeutics是一家临床阶段的肿瘤学公司，专注于开发MasterKey疗法，以解决临床验证的靶标中的致癌突变家族。该公司的MasterKey疗法旨在针对广泛的基因定义的患者群体，克服耐药性，最大限度地减少野生型介导的毒性，并具有大脑穿透力来治疗中枢神经系统疾病。该公司正在推进两个临床阶段的项目：BDTX-1535，一种靶向表皮生长因子突变体NSCLC和GBM的第四代表皮生长因子MasterKey抑制剂，以及一种针对实体瘤KRAS、NRAS和BRAF改变的脑穿透性RAF MasterKey抑制剂 BDTX-4933。欲了解更多信息，请访问 www.blackdiamondther
Contacts
联系人
For Investors:
Mario Corso, Head of Investor Relations, Black Diamond Therapeutics
mcorso@bdtx.com
对于投资者：
马里奥·科尔索，Black Diamond Therapeutics投资者关系主管
mcorso@bdtx.com
For Media:
media@bdtx.com
对于媒体：
media@bdtx.com